Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Biosimilars: Expanding Access to Precision Medicine through Affordable Biologic Therapies

IDEAYA Biosciences Secures Exclusive Worldwide License for Biocytogen’s BsADC Program IDE034 for Solid Tumor Treatment

Home
/
update
/
details

Predictive Oncology Enters Biomarker Discovery Market Following Successful Ovarian Cancer Study Results

NextEdge Admin

25 Jul 2024

2 min 17 sec

Predictive Oncology , a leader in AI-driven drug discovery and biologics, announced the expansion of its AI/ML-driven platform to discover novel biomarkers for predicting patient outcomes and drug response in oncology. This initiative follows the successful results from a retrospective ovarian cancer study with UPMC Magee-Womens Hospital, presented at the 2024 ASCO Annual Meeting. The study developed multi-omic machine learning models that predicted short-term and long-term survival outcomes more accurately than clinical data alone, supporting novel ovarian cancer biomarker discovery.

Arlette H. Uihlein, MD, SVP, highlighted that their platform uses diverse patient samples to predict drug responses accurately and is now applying deep learning for biomarker discovery related to overall survival and drug response. Raymond Vennare, CEO, emphasized the potential for developing a clinical decision support tool and further biomarker discovery for other cancer types through collaborations with biopharmaceutical partners and healthcare networks.

The biomarker discovery market is estimated to be $51.5 billion in 2024. Predictive Oncology released a white paper detailing its biomarker discovery capabilities, accessible at their website.

Predictive Oncology utilizes AI and machine learning to expedite biomarker and drug discovery, benefiting cancer patients globally. Their AI platform, PEDAL, predicts tumor sample responses to drugs with 92% accuracy, supported by a biobank of over 150,000 human tumor samples. They offer comprehensive AI-based drug discovery solutions, complemented by a CLIA lab and GMP facilities, headquartered in Pittsburgh, PA.